404010-35-1

Upstream product

• 473269-70-4 5-tert-butyl-2-methoxybenzene-1,3-diamine 
• 124-63-0 methanesulfonyl chloride 
• 5396-38-3 1-(tert-butyl)-4-methoxybenzene 
• 404010-31-7 5-tert-Butyl-2-methoxy-3-nitroaniline 
• 695179-07-8 N-(3-amino-5-tert-butyl-2-methoxy-phenyl)-methanesulphonamide hydrochloride 
• 404010-33-9 N-(3-nitro-5-tert-butyl-2-methoxy-phenyl)-methanesulfonamide 
• 77055-30-2 5-tert-butyl-2-methoxy-1,3-dinitrobenzene 

Downstream Products

• 616238-83-6 4-nitro-benzo[b]thiophene-2-carboxylic acid (5-tert-butyl-3-methanesulfonylamino-2-methoxy-phenyl)-amide 
• 616238-60-9 N-[2-(5-tert-butyl-3-methanesulfonylamino-2-methoxy-phenylcarbamoyl)-benzo[b]thiophen-7-yl]-6-chloronicotinamide 
• 616238-89-2 1-methyl-7-nitroindole-2-carboxylic acid (5-tert-butyl-3-methanesulfonylamino-2-methoxy-phenyl)-amide 
• 473269-94-2 N-(5-tert-butyl-2-methoxy-3-{3-[4-(2-oxo-2H-pyran-4-yloxy)-naphthalen-1-yl]-ureido}-phenyl)-methanesulfonamide 
• 1215385-59-3 methyl 2-(5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenylcarbamoyl)-1-methyl-1H-indole-7-carboxylate 

Relevant academic research and scientific papers

Novel chromene diarylurea compounds, and preparation method and application thereof

The invention relates to compounds represented by the general formula I, or isomers, pharmaceutical salts and solvates thereof; the invention also relates to a composition containing the compounds represented by the general formula I, or the isomers, the

KINASE INHIBITOR

There is provided a compound of formula (I), which compound has antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases, e.g., Src and Lck) and has use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

KINASE INHIBITORS

There are provided compounds of formula I, wherein R1A to R1E, R2 to R5, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

UREA DERIVATIVES USEFUL AS KINASE INHIBITORS

There are provided compounds of formula I, wherein R1A to R1E, R2 to R5, L and X1 to X3 have meanings given in the description, which compounds have antiinflammatory activity (e.g. through inhibition of one or more of members of: the family of p38 mitogen-activated protein kinase enzymes; Syk kinase; and members of the Src family of tyrosine kinases) and have use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, eye and intestines.

7-(Piperazine-1-Ymethyl)-1H-Indole-2-Carboxylic Acid (Phenyl)-Amide Derivatives and Allied Compounds as P38 Map Kinase Inhibitors for the Treatment of Respiratory Diseases

The present invention provides compounds according to general formula (I) which are proposed for the treatment of respiratory complaints, particularly asthma and COPD.

Discovery and optimization of p38 inhibitors via computer-assisted drug design

Integration of computational methods, X-ray crystallography, and structure-activity relationships will be disclosed, which lead to a new class of p38 inhibitors that bind to p38 MAP kinase in a Phe out conformation.

Sulfonamide intermediates and methods of producing same

Disclosed are intermediates of the formula (A) and methods of making same. The intermediate compounds are useful in the synthesis of heteroaryl/aryl urea compounds,

1,4-Disubstituted benzo-fused compounds

Disclosed are novel 1,4-disubstituted benzo-fused compounds wherein G, X, L, Q, n and Y are defined herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic infla

Compounds useful as anti-inflammatory agents

Disclosed are novel aromatic compounds of the formula(I) wherein G, E, W, Ar, X, Y and Z. The compounds are useful for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are pharmaceutical compositions containing and processes of making such compounds.

Compounds useful as anti-inflammatory agents

Disclosed are novel aromatic compounds of the formula(I) wherein G, E, W, Ar, X, Y and Z. The compounds are useful for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are pharmaceutical compositions containing and processes of making such compounds.